The Effects of the Endocrine System on Endometrial Cancer
This trial is active, not recruiting.
|Sponsor||Queensland Centre for Gynaecological Cancer|
|Collaborator||Greenslopes Private Hospital|
|Start date||October 2009|
|End date||August 2011|
|Trial size||80 participants|
|Trial identifier||NCT01075386, Endo01|
Endometrial cancer usually begins in the endometrium, which is the tissue lining of the uterus. Endometrial cancer is the most commonly diagnosed gynaecological malignancy in Australia. It affects 1 in 80 Australian women and there are about 1400 new cases and 260 deaths from the disease every year. Most affected women are aged between 50 and 70 years. The purpose of this study is to investigate the possible role of the endocrine system in the regulation of human endometrial cancer. By looking at the laboratory results of people with endometrial cancer and also those without endometrial cancer we hope to gain a better understanding of how endometrial cancer develops and progresses. This may lead to the development of new, effective therapies for endometrial cancer.
|Observational model||case control|
Patients with Endometrial cancer of Grade 1 differentiation
Patients without endometrial cancer
Patients with Endometrial cancer of Grade 2 differentiation
Patients with Endometrial cancer of Grade 3 differentiation
Female participants at least 18 years old.
Inclusion Criteria: - women aged 18 years or older - having a hysterectomy for the treatment of endometrial cancer, fibroids, chronic pelvic pain or abnormal uterine bleeding - have provided informed consent
|Official title||Expression and Function of Ghrelin and Its Receptor, Growth Hormone Secretagogue Receptor TWEAK Protein and Its Receptor Fn14 in Human Endometrial Cancer|
Call for more information